These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 14691655)

  • 1. A prospective comparison of the effect of interferon-alpha and interferon-beta treatment in patients with chronic hepatitis C on the incidence of hepatocellular carcinoma development.
    Kashiwagi K; Furusyo N; Kubo N; Nakashima H; Nomura H; Kashiwagi S; Hayashi J
    J Infect Chemother; 2003 Dec; 9(4):333-40. PubMed ID: 14691655
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term outcome after interferon therapy in elderly patients with chronic hepatitis C.
    Arase Y; Ikeda K; Suzuki F; Suzuki Y; Saitoh S; Kobayashi M; Akuta N; Someya T; Koyama R; Hosaka T; Sezaki H; Kobayashi M; Kumada H
    Intervirology; 2007; 50(1):16-23. PubMed ID: 17164553
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term responders without eradication of hepatitis C virus after interferon therapy: characterization of clinical profiles and incidence of hepatocellular carcinoma.
    Yabuuchi I; Imai Y; Kawata S; Tamura S; Noda S; Inada M; Maeda Y; Shirai Y; Fukuzaki T; Kaji I; Ishikawa H; Matsuda Y; Nishikawa M; Seki K; Matsuzawa Y
    Liver; 2000 Jul; 20(4):290-5. PubMed ID: 10959807
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term interferon monotherapy reduces the risk of HCV-associated hepatocellular carcinoma.
    Takeyasu M; Akuta N; Suzuki F; Seko Y; Kawamura Y; Sezaki H; Suzuki Y; Hosaka T; Kobayashi M; Kobayashi M; Arase Y; Ikeda K; Kumada H
    J Med Virol; 2012 Aug; 84(8):1199-207. PubMed ID: 22711347
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interferon-induced prolonged biochemical response reduces hepatocarcinogenesis in hepatitis C virus infection.
    Arase Y; Ikeda K; Suzuki F; Suzuki Y; Kobayashi M; Akuta N; Hosaka T; Sezaki H; Yatsuji H; Kawamura Y; Kobayashi M; Kumada H
    J Med Virol; 2007 Oct; 79(10):1485-90. PubMed ID: 17705189
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of background factors influencing long-term prognosis of patients with chronic hepatitis C treated with interferon.
    Yoneyama K; Yamaguchi M; Kiuchi Y; Morizane T; Shibata M; Mitamura K
    Intervirology; 2002; 45(1):11-9. PubMed ID: 11937766
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of the dose and duration of interferon-alpha therapy on the incidence of hepatocellular carcinoma in noncirrhotic patients with a nonsustained response to interferon for chronic hepatitis C.
    Toyoda H; Kumada T; Nakano S; Takeda I; Sugiyama K; Kiriyama S; Sone Y; Tanikawa M; Hisanaga Y; Hayashi K; Honda T
    Oncology; 2001; 61(2):134-42. PubMed ID: 11528252
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of interferon retreatment after relapse for chronic hepatitis C patients with biochemical response after first interferon therapy.
    Arase Y; Ikeda K; Tsubota A; Suzuki Y; Saitoh S; Kobayashi M; Suzuki F; Akuta N; Someya T; Hosaka T; Kobayashi M; Kumada H
    J Gastroenterol; 2004; 39(5):455-60. PubMed ID: 15175944
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical characteristics of patients with chronic hepatitis C showing biochemical remission, without hepatitis C virus eradication, as a result of interferon therapy. The Osaka Liver Disease Study Group.
    Kasahara A; Hayashi N; Mochizuki K; Hiramatsu N; Sasaki Y; Kakumu S; Kiyosawa K; Okita K
    J Viral Hepat; 2000 Sep; 7(5):343-51. PubMed ID: 10971822
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of twice-daily administration of interferon-beta for chronic hepatitis C.
    Kakizaki S; Takagi H; Yamada T; Ichikawa T; Abe T; Sohara N; Kosone T; Kaneko M; Takezawa J; Takayama H; Nagamine T; Mori M
    J Viral Hepat; 1999 Jul; 6(4):315-9. PubMed ID: 10607246
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The incidence of hepatocellular carcinoma in patients with chronic hepatitis C after interferon treatment.
    Miyajima I; Sata M; Kumashiro R; Uchimura Y; Ide T; Suzuki H; Tanikawa K
    Oncol Rep; 1998; 5(1):201-4. PubMed ID: 9458322
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk factors for hepatocellular carcinoma in hepatitis C patients with normal alanine aminotransferase treated with pegylated interferon and ribavirin.
    Harada N; Hiramatsu N; Oze T; Morishita N; Yamada R; Hikita H; Miyazaki M; Yakushijin T; Miyagi T; Yoshida Y; Tatsumi T; Kanto T; Kasahara A; Oshita M; Mita E; Hagiwara H; Inui Y; Katayama K; Tamura S; Yoshihara H; Imai Y; Inoue A; Hayashi N; Takehara T
    J Viral Hepat; 2014 May; 21(5):357-65. PubMed ID: 24716638
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Post-treatment levels of α-fetoprotein predict incidence of hepatocellular carcinoma after interferon therapy.
    Oze T; Hiramatsu N; Yakushijin T; Miyazaki M; Yamada A; Oshita M; Hagiwara H; Mita E; Ito T; Fukui H; Inui Y; Hijioka T; Inada M; Katayama K; Tamura S; Yoshihara H; Inoue A; Imai Y; Hayashi E; Kato M; Miyagi T; Yoshida Y; Tatsumi T; Kasahara A; Hamasaki T; Hayashi N; Takehara T;
    Clin Gastroenterol Hepatol; 2014 Jul; 12(7):1186-95. PubMed ID: 24321207
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Varying incidence of cirrhosis and hepatocellular carcinoma in patients with chronic hepatitis C responding differently to interferon therapy.
    Shindo M; Ken A; Okuno T
    Cancer; 1999 May; 85(9):1943-50. PubMed ID: 10223234
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk factors for the development of hepatocellular carcinoma among patients with chronic hepatitis C who achieved a sustained virological response to interferon therapy.
    Tokita H; Fukui H; Tanaka A; Kamitsukasa H; Yagura M; Harada H; Okamoto H
    J Gastroenterol Hepatol; 2005 May; 20(5):752-8. PubMed ID: 15853990
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis.
    Nishiguchi S; Kuroki T; Nakatani S; Morimoto H; Takeda T; Nakajima S; Shiomi S; Seki S; Kobayashi K; Otani S
    Lancet; 1995 Oct; 346(8982):1051-5. PubMed ID: 7564784
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sustained HCV clearance by interferon-based therapy reduces hepatocellular carcinoma in hepatitis B and C dually-infected patients.
    Hung CH; Lu SN; Wang JH; Hu TH; Chen CH; Huang CM; Lee CM
    Antivir Ther; 2011; 16(7):959-68. PubMed ID: 22024511
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interferon therapy for 2 years or longer reduces the incidence of hepatocarcinogenesis in patients with chronic hepatitis C viral infection.
    Arase Y; Ikeda K; Tsubota A; Suzuki F; Suzuki Y; Saitoh S; Kobayashi M; Akuta N; Someya T; Hosaka T; Sezaki H; Kobayashi M; Kumada H
    Intervirology; 2004; 47(6):355-61. PubMed ID: 15564748
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of diabetes mellitus on incidence of hepatocellular carcinoma in chronic hepatitis C patients treated with interferon-based antiviral therapy.
    Hung CH; Lee CM; Wang JH; Hu TH; Chen CH; Lin CY; Lu SN
    Int J Cancer; 2011 May; 128(10):2344-52. PubMed ID: 20669224
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The incidence and risk factors for the development of hepatocellular carcinoma after peginterferon plus ribavirin therapy for chronic hepatitis C.
    Dohmen K; Kawano A; Takahashi K; Shigematsu H; Tanaka H; Haruno M; Yanagita K; Ichiki Y; Mori T; Hayashida K; Shimoda S; Ishibashi H; Nomura H
    Hepatogastroenterology; 2013; 60(128):2034-8. PubMed ID: 24719946
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.